Hunan Er-kang Pharmaceutical (300267.SZ) controlling shareholder Shuai Fangwen plans to reduce their shareholding by no more than 2.04%.
Erkang Pharmaceuticals (300267.SZ) announced that Mr. Shuai Fangwen, the controlling shareholder of the company, plans to reduce his holdings of the company's shares by a total of up to 42 million shares from April 23, 2026 to July 22, 2026 through centralized bidding or block trading, which is not more than 2.04% of the company's total share capital.
Hunan Er-kang Pharmaceutical (300267.SZ) announced that Mr. Shuai Fangwen, the controlling shareholder of the company, plans to reduce his holdings in the company by a total of no more than 42 million shares, or 2.04% of the total share capital, through centralized bidding or block trading from April 23, 2026 to July 22, 2026.
Related Articles
In 2026, the new NIO 5566 model will be launched, and the Hong Kong stock market closed at noon skyrocketed by over 9%.
Poly Property (00119) 2025 Annual Report: Continuous optimization of structure, sales among top fifteen
On March 31st, MNSO (09896) spent 396,900 USD to repurchase 98,100 shares.
In 2026, the new NIO 5566 model will be launched, and the Hong Kong stock market closed at noon skyrocketed by over 9%.
Poly Property (00119) 2025 Annual Report: Continuous optimization of structure, sales among top fifteen
On March 31st, MNSO (09896) spent 396,900 USD to repurchase 98,100 shares.
